STOCK TITAN
  1. Home
  2. Sec-filings
  3. NVS
  4. [SCHEDULE 13G] Novartis AG SEC Filing

[SCHEDULE 13G] Novartis AG SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock NVS logo
Novartis

NYSE:NVS

NVS Rankings

#43 Ranked by Market Cap
#1176 Ranked by Dividends

NVS Latest News

Sep 3, 2025
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
Aug 11, 2025
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
Jul 31, 2025
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Jul 3, 2025
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
Apr 2, 2025
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

NVS Latest SEC Filings

Aug 11, 2025
[6-K] Novartis AG Current Report (Foreign Issuer)
Jul 17, 2025
[6-K] Novartis AG Current Report (Foreign Issuer)
Jul 17, 2025
[6-K] Novartis AG Current Report (Foreign Issuer)

NVS Stock Data

248.23B
1.94B
0%
7.05%
0.23%
Drug Manufacturers - General
Healthcare
Link
Switzerland
Basel